Dr Edouard Begon,
Secrétaire Général de Resopso
Dermatologue, praticien hospitalier, Chef de service CH Pontoise (95), consultation psoriasis Hôpital Saint-Louis Paris (75)
 Li H. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020 Apr 17.
 Bouaziz JD et al. Vascular skin symptoms in COVID-19: a french observational study. J Eur Acad Dermatol Venereol Apr 27.
 Henderson LA et al. On the alert for cytokine storm: Immunopathology in COVID-19. Arthritis Rheumatol. 2020. Apr 15
 Feldmann M et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020. Apr
 Ritchie AL et al. Immunosuppression for hyperinflammation in COVID-19: a double-edged sword? Lancet. 2020. Apr
 Lagunas-Rangel FA. High IL-6/IFN-γ ratio could be associated with severe disease in COVID-19 patient. J Med Virol. 2020.
 Amerio P et al. COVID-19 and psoriasis : should we fear for patients treated with biologics? Dermatol Ther. 2020. Apr
 Megna M et al. Biologics for psoriasis in COVID-19 era: what do we know? Dermatol Ther. 2020. Apr 27
 Torres T el al. Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. Am J Clin Dermatol. 2020
 Hui DS et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018
 Lebwohl M et al. Should biologics for psoriasis be interrupted in the era of COVID-19? J Am Acad Dermatol.2020 May
 Li X. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020 Apr 12
 Gianfrancisco MA et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol. 2020 April 16.
 Monti S et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis. 2020. May
 Gisondi P et al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. Br J Dermatol. Apr 28
 Conforti C et al. COVID-19 and psoriasis: Is it time to limit treatment with immunosuppressants? A call for action. Dermatol Ther. 2020. Mar
 Price KN et al. COVID-19 and immunomodulator/immunosuppressant use in dermatology. J Am Acad Dermatol. 2020. May
 Ceribelli A. Recommendations for coronavirus infection in rheumatic diseases treated with biologic therapy. J Autoimmun. 2020.may.
 Wollenberg A et al. European Task Force on Atopic Dermatitis (ETFAD) statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)-infection and atopic dermatitis. J Eur Acad Dermatol Venereol. 2020. Mar
 Mehta P. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020. Mar
 Gisondi P et al. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. J Eur Acad Dermatol Venereol. 2020
 Freeman EE et al. Creating Dermatology Guidelines for Covid-19: The Pitfalls of Applying Evidence Based Medicine to an Emerging Infectious Disease. J Am Acad Dermatol. 2020. Apr
 Shap P et al. Use of systemic immunomodulatory therapies during the coronavirus disease 2019 (COVID-19) pandemic. J Am Acad Dermatol. 2020. Apr
 Megna M et al. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears. J Dermatol Treat. 2020. Apr
 Damiani G et al. Biologics increase the risk of SARS- CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration. Dermatol Ther. 2020